Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the firms behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 115,000 investors, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS investors have turned bullish on Eli Lilly
Increased sales from key drugs Cymbalta and Cialis -- the latter competes against Pfizer’s
On the down side, Eli Lilly's anchor antipsychotic drug Zyprexa continues to fare well, but it will face some new competition this year from generic versions of Johnson & Johnson’s
With current blockbusters going off patent, Eli Lilly wants to control costs and move drugs to market faster. This motivated a $1.6 billion deal with Covance and a recent boost to its animal health division by acquiring the Posilac cow hormone from Monsanto
The Motley Fool Income Investor service scours the market for solid investments paying investors money to hold shares. See which dividend-paying firms the team is recommending today with a free 30-day trial.
Fool contributor Dave Mock sorely needs an upgrade for his wardrobe. He owns shares of Pfizer and Johnson & Johnson and is the author of The Qualcomm Equation. Pfizer, Eli Lilly, and Johnson & Johnson are Income Investor picks. Pfizer is also an Inside Value recommendation. The Fool's disclosure policy issues citations for flagrant violations.